Trial Profile
Intra-arterial Lutetium-177-dotatate for Treatment of Patients With Neuro-endocrine Tumor Liver Metastases
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 09 Nov 2022
Price :
$35
*
At a glance
- Drugs Lutetium-(177Lu)-oxodotreotide (Primary) ; Lutetium-(177Lu)-oxodotreotide
- Indications Neuroendocrine tumours
- Focus Therapeutic Use
- Acronyms LUTIA
- 07 Nov 2022 Status changed from recruiting to completed.
- 15 Jun 2020 Planned End Date changed from 1 Aug 2021 to 1 Sep 2021.
- 15 Jun 2020 Planned primary completion date changed from 1 Jan 2021 to 1 Sep 2021.